Rutgers Cancer Institute of New Jersey
195 Little Albany Street
New Brunswick, NJ 08903-2681
Our laboratory focuses on understanding the interplay between infections, cancer, and the immune system. We have discovered that non-oncogenic infections (those that do not directly cause cancer) regulate tumor occurrence and growth (in both negative and positive ways). Therefore, we strive to understand the mechanism underlying these effects and to translate our findings toward patient therapies against cancer.
Our Cell Reports article “Non-oncogenic acute viral infections disrupt anti-cancer responses and lead to accelerated cancer-specific host death” is now published.
Access the article here
Congrats to the Zloza Laboratory on the funding of their study “Autologous double-humanized mouse model for the study of Pembrolizumab” (MISP # 55542) by Merck Sharp & Dohme Corp.
The Zloza Laboratory has been awarded research funding from Gateway For Cancer Research for their proposed collaborative work with the Kaufman Laboratory (Rutgers) on the study “Combination Oncolytic Virus and PD-1 Blockade for Melanoma Treatment” (PI: Kaufman, Co-I: Zloza)
Congrats to the Zloza Laboratory on the acceptance of their manuscript “Low dose interleukin-2 (IL-2) impairs host anti-tumor immunity and inhibits therapeutic responses” for publication in Cancer Immunology, Immunotherapy in collaboration with the Kaufman Laboratory at Rutgers Cancer Institute.
Congrats to the Zloza Laboratory on the acceptance of their manuscript “Non-oncogenic acute viral infections disrupt anti-cancer responses and lead to accelerated cancer-specific host death” for publication in Cell Reports.
Toward this effort we utilize a double-humanized patient-derived xenograft model and novel biotechnologies that we have developed. These allow us to conduct in vivo studies of a patient’s anti-cancer immune response in the context of that patient’s intact tumor microenvironment, and to efficiently target our therapies to the tumor microenvironment. Our goals are to discover new cancer immunotherapies and to develop a unified theory of infection, cancer, and autoimmunity.
We welcome inquiries about our research and new collaboration opportunities. Please contact us!